1 Lee S, Kim JM, Chung CS, Cho KJ, Kim JH.Polymorphism in CYP2C9 as a non-critical factor of warfarin dosage adjustment in Korean patients[J].Arch Pharm Res, 2003;26(11):967-72
2 Schwarz UI.Clinical relevance of genetic polymorphisms in the human CYP2C9 gene[J].Eur J Clin Invest, 2003;33(2):23-30
3 Bozina N, Granic P, Lalic Z, Tramisak I, Lovric M, Stavljenic RA.Genetic polymorphisms of cytochromes P450:CYP2C9, CYP2C19, and CYP2D6 in Croatian population[J].Croat Med J, 2003;44(4):425-8
4 Yang JQ, Morin S, Verstuyft C, Fan LA, Zhang Y, Xu CD, et al.Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations[J].Fundam Clin Pharmacol, 2003;17(3):373-6
5 Takahashi H, WilkinsonGR, Caraco Y, Muszkat M, Kim RB, Kashima T, et al.Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients[J].Clin Pharmacol Ther, 2003;73(3):253-63
6 Xie HG, Prasad HC, Kim RB,Stein CM.CYP2C9 allelic variants:ethnic distribution and functional significance[J].Adv Drug Deliv Rev, 2002;54(10):1257-70
7 Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP, Shimada T.Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian Populations[J].Pharmacogenetics, 1997;7(2):103-113
8 Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT.Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and in an individual homozygous for the CYP2C9 ＊3 allele[J].Pharmacogenetics, 1999:9(1):71-80
9 Van der Weide J, Steijns LS, van Weelden MJ, de Haan K. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement[J].Pharmacogenetics, 2001;11(4):287-91
10 Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R.Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance[J].Clin Pharmacol Ther, 2002;72(6):702-10
11 Yoon YR, Shon JH, Kim MK, Lim YC, Lee HR, Park JY, et al.Frequency of cytochrome P450 2C9 mutant alleles in a Korean population[J].Br J Clin Pharmacol, 2001;51(3):277-80
12 Aithal GP, Day CP, Kesteven PJ, Daly AK.Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications[J].Lancet, 1999;353(9154):717-9
13 Lee CR, Pieper JA, Hinderliter AL, Blaisdell JA, Goldstein JA.Evaluation of cytochrome P450 2C9 metabolic activity with tolbutamide in CYP2C9 heterozygotes [J].Clin Pharmacol Ther, 2002;72(5):562-71
14 Miners JO, Birkett DJ.Cytochrome P450 2C9:an enzyme of major importance in human drug metabolism[J].Br J Clin Pharmacol, 1998;45(6):525-38
15 McCrea JB, Cribb A, Rushmore T, Osborne B, Gillen L, Lo MW, et al.Phenotypic and genotypicinvestigations of a healthy volunteer deficient in the conversion oflosartan to its active metabolite E-3174[J].Clin Pharmacol Ther, 1999;65(3):348-52
16 卢爱华, 舒焱, 周宏灏.细胞色素氧化酶CYP2C9 的研究进展[J].中国临床药理学杂志, 2000;16(5):381-85
17 Miners JO, Coulter S, Birkett DJ, Goldstein JA.Torsemidemetabolism by CYP2C9 variants and Other human CYP2C subfamily enzymes[J].Pharmacogenetics, 2000;10(3):267-70
18 Huang SI, Hiratsuka M.Allele and genotype frequencies of polymophic Cytochromes P450 (2C9, 2C19, 2E1)and dihydropynmidine dehydrogenase (DPYD) in the Egyptian population [J].Br J Clin Pharmacol, 2002;53(6):596-603 |
